Vireo Growth (VREOF) EBITDA Margin (2020 - 2026)
Vireo Growth (VREOF) reported EBITDA Margin of 8.47% for Q1 2026, up 31.0% on a YoY basis from 6.47% in Q1 2025, and up 588.13% sequentially from 1.74% in Q4 2025.
Vireo Growth (VREOF) EBITDA Margin (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of EBITDA Margin data on file, last reported at 8.47% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 31.0% year-over-year to 8.47%; the trailing twelve-month figure through Mar 2026 stood at 1.71% (down 912.0% YoY), and the FY2025 full-year result was 0.39%, down 1404.0% from the prior year.
- EBITDA Margin improved to 8.47% in Q1 2026, from 1.74% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 23.8% in Q3 2023 to a low of 49.62% in Q1 2022.
- A 5-year average of 3.75% and a median of 1.93% in 2023 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin soared 6416 bps in 2022 and slumped 2728 bps in 2025, its largest moves.
- Tracing VREOF's EBITDA Margin over 5 years: stood at 3.69% in 2022, then surged by 504 bps to 22.26% in 2023, then tumbled by 115 bps to 3.36% in 2024, then soared by 48 bps to 1.74% in 2025, then jumped by 588 bps to 8.47% in 2026.
- Business Quant data shows VREOF's EBITDA Margin at 8.47% in Q1 2026, 1.74% in Q4 2025, and 0.88% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 8.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.47% |
| Dec 31, 2025 | -1.74% |
| Sep 30, 2025 | 0.88% |
| Jun 30, 2025 | -4.20% |
| Mar 31, 2025 | 8.16% |
| Dec 31, 2024 | -3.36% |
| Sep 30, 2024 | 15.30% |
| Jun 30, 2024 | 23.08% |
| Mar 31, 2024 | 19.76% |
| Dec 31, 2023 | 22.26% |
| Sep 30, 2023 | 23.80% |
| Jun 30, 2023 | -5.16% |
| Mar 31, 2023 | 1.93% |
| Dec 31, 2022 | 3.69% |
| Sep 30, 2022 | -1.00% |
| Jun 30, 2022 | 1.46% |
| Mar 31, 2022 | -49.62% |
| Dec 31, 2021 | -60.47% |
| Sep 30, 2021 | -30.90% |
| Jun 30, 2021 | -22.82% |